Mesoblast secures FDA approval for heart disease treatment Biotechnology company Mesoblast has secured US Food and Drug Administration (FDA) approval for its Revascor heart disease treatment. The FDA issued a rare pediatric disease (RPD) designation for Revascor following submission of results from a trial in 19 children with hypoplastic left heart syndrome (HLHS). Revascor is…
What were the five biggest stories of the year? Here’s what visitors to this site were reading. 5) Australia’s 50 most innovative manufacturers revealed @AuManufacturing and the Australian Manufacturing Forum’s first quest to identify Australia’s 50 most innovative manufacturers ended in July, and a second iteration of the series kicked off last month. We learned…
The Group CEO of the biggest Australian-owned supplier of military munitions has laid out a detailed plan to mobilise the nation’s defence industrial base, emphasising “it’s time for urgency, optimism and action”. Speaking to the National Press Club in Canberra, NIOA Group CEO Robert Nioa released a report which calls on the Australian Government to…
Australian owned munitions manufacturer NIOA Group has taken up a tenancy at the United States Army’s Joint Centre of Excellence for ammunition and weapons, Picatinny Arsenal in New Jersey. The further expansion into the US follows NIOA’s 100 per cent acquisition earlier this year of Tennessee-based Barrett Firearms, and shows a determination to significantly enter…
